ARTIFICIAL INTELLIGENCE AND PRECISSION MEDICINE IN ONCOLOGY

Dr. Pottier is a specialist in rare tumors and early-phase clinical research, recognized by numerous prestigious academic honors in Belgium.

Academic Titles & Degrees:  MD and PhD (University of Liège); Inter-university Diploma in the “Diagnosis and Management of Sarcomas and Mesenchymal Tumors” (Paris Cité University).

Current Executive & Clinical Appointments:  Chief Resident in Medical Oncology at CHU de Liège; Faculty at the University of Liège.

Research Axes & Leadership:  Management of the sarcoma section at CHU de Liège and leadership of Phase 1 clinical trials (DITEP seminars at Gustave Roussy).

High-Impact Publications & Awards: Recipient of the Royal Academy of Medicine Prize and the “Fondation Henri Lempereur.”

Dr. Onesty’s international trajectory—spanning Rome, Gustave Roussy, and Liège—underscores her expertise in fundamental cancer research and clinical trial management.

Academic Titles & Degrees:  MD (University of Rome “Sapienza”); PhD (University of Liège, GIGA Research Center); Research Fellow (Institut de Cancérologie Gustave Roussy).

Current Executive & Clinical Appointments: Medical Oncologist at IRCCS National Cancer Institute “Regina Elena” (Rome).

Research Axes & Leadership: High expertise in translational cancer research and sub-investigation of clinical trials.

High-Impact Publications & Awards: Author and co-author of more than fifty articles and abstracts in international oncology. The research presented by these specialists informs the following section, which focuses on the direct implementation of findings within high-level clinical and surgical settings.

MSc Mosquera represents the strategic integration of mechatronics and digital engineering into the medical landscape, particularly through “Industry 4.0” applications.

Academic Titles & Degrees: MSc in Mechatronics and Digital Engineering.

Current Executive & Clinical Appointments:  Director of the Mechatronics School at Universidad Internacional del Ecuador (UIDE).

Research Axes & Leadership: Development of “Digital Twins” for robotic arms, facilitating the simulation of advanced robotic surgical systems; high-efficiency solar technology; integration of mechatronic design in community outreach.

Dr. Velasco Díez is a global authority on autophagy and cannabinoid signaling, exploring their potential to treat aggressive brain tumors through personalized molecular targeting.

Academic Titles & Degrees: PhD in Biochemistry and Molecular Biology (Complutense University of Madrid).

Current Executive & Clinical Appointments:  Full Professor at Complutense University; President of the Spanish Society for Autophagy Research (SEFAGIA).

Research Axes & Leadership: Elucidating cannabinoid antitumor activity; personalized glioblastoma therapies targeting the MDK/ALK axis; FLASH radiotherapy research using tissue-on-chip devices.

High-Impact Publications & Awards:   Nature Reviews Cancer, Cancer Cell, Nature Cell Biology, EMBO Journal, Journal of Experimental Medicine.

Dr. Berchem serves as the vital conduit between the Luxembourg Institute of Health (LIH) and frontline clinical practice, specializing in the translation of functional molecular data into actionable oncology strategies.

Academic Titles & Degrees: MD (Université Libre de Bruxelles); PhD (Paris-Sud University/Gustave Roussy); Postdoctoral Fellowship (Lombardi Comprehensive Cancer Center, Georgetown University).

Current Executive & Clinical Appointments:  Head of the Department of Hemato-Oncology at Centre Hospitalier de Luxembourg; Associate Medical Director at the Luxembourg Institute of Health (LIH); Honorary Professor of Medical Oncology at the University of Luxembourg; President of the Institut National du Cancer (INC).

Research Axes & Leadership: Governance of over 50 clinical trials across lung cancer, melanoma, myeloma, and urological tumors. His recent research includes personalized functional profiling in spheroids for metastatic colorectal cancer and the investigation of anti-PD-1 immunotherapy via the Ackr2 receptor in melanoma.

Legacy Journals:

• The New England Journal of Medicine (NEJM)
• The Lancet
• Nature Communications
• NPJ Precision Oncology
• Blood
• Science Advances
• Cancer Research

Dr. Jerusalem maintains profound influence on international standard-of-care through his roles on steering committees for landmark global clinical trials.

Academic Titles & Degrees:  MD and PhD (University of Liège).

Current Executive & Clinical Appointments:  Head of Medical Oncology and Director of the Breast Clinic at CHU de Liège; Professor of Medical Oncology; Principal Investigator for EORTC, IBCSG, and BCIRG.

Research Axes & Leadership: Leadership in international trials including CONFIRM, BOLERO 3/6, SOLE, MONALEESA 3, and APHINITY .

High-Impact Publications & Awards:   The Lancet Oncology, Journal of Clinical Oncology (JCO), Annals of Oncology, Cancer Research.

Following elite training at Memorial Sloan Kettering (MSK) and Gustave Roussy, Dr. Peeters has transitioned into major leadership roles influencing European gastrointestinal oncology.

Academic Titles & Degrees: MD and PhD (Katholieke Universiteit Leuven); Specialist in Hepato-Gastroenterology.

Current Executive & Clinical Appointments:  CEO and Chairman of Qurin BV; Medical Director of Elmedix BV; Full Professor of Oncology at the University of Antwerp.

Research Axes & Leadership: Leadership in European gastrointestinal oncology trials (PETACC-1, PETACC-3); expert auditor for the European Neuroendocrine Tumor Society (ENETS).

Dr. Cabezas has exerted a transformative impact on Latin American educational and health systems by fostering strategic collaborations with European and Canadian academic organizations.

Academic Titles & Degrees:  MD and PhD (University of Liège); Specialty training in Epidemiology (Erasmus University); Problem-Based Learning certification (Maastricht University).

Current Executive & Clinical Appointments:  General Manager of Health & Research Services; Researcher Professor at Universidad Internacional Ecuador (UIDE); Committee member for international scientific journals indexed in ScienceDirect.

Research Axes & Leadership:  Coordination of Phase I–IV clinical trials with a specialized focus on epidemiology and the public health implications of pharmacoeconomics.

Specialized Training Portfolio: Training Focus | Institution || Epidemiology | Erasmus University (Rotterdam) || Problem-Based Learning | Maastricht University || Specialty & Doctorate | University of Liège (ULg) || Clinical Trial Governance | Health & Research Services |

The strategic oversight provided by this committee ensures the scientific integrity and global clinical relevance of the research presented by the distinguished speakers.

Dr. Nokin’s work is critical in identifying the metabolic drivers that facilitate therapeutic resistance in lung and prostate cancers.

Academic Titles & Degrees:  MD and PhD (University of Liège); MSc in Biomedical Sciences.

Current Executive & Clinical Appointments:  Assistant Professor at the Laboratory of Tumor and Developmental Biology (GIGA-Cancer), University of Liège.

Research Axes & Leadership: Investigation of metabolic vulnerabilities and therapeutic resistance in lung adenocarcinoma; study of Dentin Matrix Protein 1 (DMP1) in human prostate cancer.

High-Impact Publications & Awards:   Nature Communications, Cancer Research, Clinical Cancer Research, Journal for Immunotherapy of Cancer.

With an h-index of 31 and over 2,800 citations, Dr. Herfs serves as a global benchmark for scientific influence in the study of viral-induced carcinogenesis.

Academic Titles & Degrees:  MSc in Biomedical Sciences; PhD in Biomedical and Pharmaceutical Sciences (University of Liège).

Current Executive & Clinical Appointments:  Research Associate with the Belgian Fund for Scientific Research (F.R.S.-FNRS) at the Laboratory of Experimental Pathology.

Research Axes & Leadership: Investigation of the tumor microenvironment and the mechanisms of immune evasion by the human papillomavirus (HPV).

High-Impact Publications & Awards:  70 academic publications; recipient of competitive Belgian grants including Télévie and FRIA.

Dr. Westerlinck bridges the gap between traditional radiation oncology and preventive digital health through technological innovation.

Academic Titles & Degrees:  MD and PhD (University of Liège); Management en Leadership voor artsen (KUL).

Current Executive & Clinical Appointments:  Chief of Clinical Service at CHU de Liège; Radiation Oncologist specializing in 4D simulation, stereotactic therapy, and IORT.

Research Axes & Leadership: Developer of the “Cancer Risk Calculator” mobile app; conducted a pivotal cost-benefit analysis of multislice cardiac CT demonstrating significant savings in intermediate-risk profiles.

High-Impact Publications & Awards: Published in European Heart Journal and the Journal of Cardiovascular Computed Tomography.

Reflecting a prestigious Harvard Medical School, Dr. Foidart focuses on aggressive tumor types through a range of highly specialized research axes, while maintaining robust clinical practice in breast cancer and gastrointestinal tumors.

Academic Titles & Degrees:  MD and PhD (University of Liège); Graduate of the Global Clinical Scholars Research Training Program at Harvard Medical School.

Current Executive & Clinical Appointments:  Senior Medical Oncologist at CHU de Liège; Professor at the University of Liège Faculty of Medicine.

Research Axes & Leadership:

• Triple-negative breast cancer: Identification of therapeutic targets and the impact of whole-genome duplication.
• Pancreatic adenocarcinoma: Research into immune sensitization and radioligands.
• Immunotherapy Toxicity: Early detection of immunotherapy-related side effects.
• High-Impact Publications & Awards:   Nature Communications, Science Translational Medicine, Cancer Cell, PNAS, Clinical Cancer Research.

Dr. Frères balances the management of clinical oncology units with sophisticated research into molecular biomarkers for treatment response.

Academic Titles & Degrees:  MD and PhD (University of Liège).

Current Executive & Clinical Appointments:  Head of the Clinical Oncology Unit at CHU de Liège; Associate Professor at the University of Liège Faculty of Medicine.

Research Axes & Leadership:  Research into circulating microRNAs (miR-34a and miR-122) as predictive markers for chemotherapy response; management of febrile neutropenia. The evolution of oncological care necessitates a shift from purely clinical observation to the precision afforded by biochemical signaling and mechatronic modeling.

Dr. Dienstmann provides a significant strategic advantage to the cohort by combining a PhD in molecular diagnostic efficiency with an MBA from ESADE. This dual background allows him to bridge the gap between clinical efficacy and system sustainability, ensuring the economic viability and scaling of precision medicine programs.

Academic Titles & Degrees: MD; PhD in Molecular Diagnostic Program Efficiency (University of Vic); MBA (ESADE Business School).

Current Executive & Clinical Appointments:  Principal Investigator of the Oncology Data Science Group at VHIO (Spain); Medical Director of the Precision Medicine and Big Data Laboratory at Oncoclínicas & Co; Editor-in-Chief of ESMO Real World Data and Digital Oncology.

Research Axes & Leadership: Strategic implementation of molecular diagnostic programs; former research fellow at Massachusetts General Hospital (Boston) and VHIO.

High-Impact Publications & Awards: Over 200 publications in peer-reviewed journals, including editorial leadership at ESMO Open.